66 related articles for article (PubMed ID: 3566291)
1. [Experimental studies on the enhanced effects of chemoendocrine therapy in breast cancer].
Abe R; Sawano A; Ueki H; Akimoto M; Kimura M
Gan To Kagaku Ryoho; 1987 Mar; 14(3 Pt 2):785-92. PubMed ID: 3566291
[TBL] [Abstract][Full Text] [Related]
2. [Synergistic effect of cell kinetics-directed chemo-endocrine therapy on experimental mammary tumors].
Ueki H
Nihon Geka Gakkai Zasshi; 1987 Nov; 88(11):1576-83. PubMed ID: 3431537
[TBL] [Abstract][Full Text] [Related]
3. [Synergistic action of lentinan (LNT) with endocrine therapy of breast cancer in rats and humans].
Kosaka A; Kuzuoka M; Yamafuji K; Imaizumi A; Hattori Y; Yamashita A
Gan To Kagaku Ryoho; 1987 Feb; 14(2):516-22. PubMed ID: 3101609
[TBL] [Abstract][Full Text] [Related]
4. Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group.
Viale G; Regan MM; Maiorano E; Mastropasqua MG; Golouh R; Perin T; Brown RW; Kovács A; Pillay K; Ohlschlegel C; Braye S; Grigolato P; Rusca T; Gelber RD; Castiglione-Gertsch M; Price KN; Goldhirsch A; Gusterson BA; Coates AS
J Clin Oncol; 2008 Mar; 26(9):1404-10. PubMed ID: 18349391
[TBL] [Abstract][Full Text] [Related]
5. Tamoxifen and 5-fluorouracil in breast cancer: cytotoxic synergism in vitro.
Benz C; Cadman E; Gwin J; Wu T; Amara J; Eisenfeld A; Dannies P
Cancer Res; 1983 Nov; 43(11):5298-303. PubMed ID: 6616464
[TBL] [Abstract][Full Text] [Related]
6. Management of breast cancer.
Cohen IA; Keller JH; Abate MA
Clin Pharm; 1982; 1(6):515-29. PubMed ID: 6192963
[TBL] [Abstract][Full Text] [Related]
7. Combination therapy of the H2712 murine mammary carcinoma with cytotoxic T lymphocytes and anti-estrogens.
Baral E; Nagy E; Kangas L; Berczi I
Anticancer Res; 1997; 17(5A):3647-51. PubMed ID: 9413217
[TBL] [Abstract][Full Text] [Related]
8. Human breast cancer cell cycle synchronization by estrogens and antiestrogens in culture.
Osborne CK; Boldt DH; Estrada P
Cancer Res; 1984 Apr; 44(4):1433-9. PubMed ID: 6704960
[TBL] [Abstract][Full Text] [Related]
9. [Breast cancer--topics from basic research].
Matsumoto K; Kuroda H; Takeyama M
Gan To Kagaku Ryoho; 1984 May; 11(5):974-80. PubMed ID: 6721515
[TBL] [Abstract][Full Text] [Related]
10. Content of epidermal growth factor receptor in metastatic breast cancer: its role in endocrine sensitivity prediction.
Nesković-Konstantinović ZB; Nikolić-Vukosavljević DB; Branković-Magić MV; Mitrovic LB; Spuzić I
Neoplasma; 2000; 47(2):107-13. PubMed ID: 10985476
[TBL] [Abstract][Full Text] [Related]
11. Antitumor action of physiological estradiol on tamoxifen-stimulated breast tumors grown in athymic mice.
Yao K; Lee ES; Bentrem DJ; England G; Schafer JI; O'Regan RM; Jordan VC
Clin Cancer Res; 2000 May; 6(5):2028-36. PubMed ID: 10815929
[TBL] [Abstract][Full Text] [Related]
12. Steroid hormone receptors as targets for the therapy of breast and prostate cancer--recent advances, mechanisms of resistance, and new approaches.
Hoffmann J; Sommer A
J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):191-200. PubMed ID: 15860262
[TBL] [Abstract][Full Text] [Related]
13. The efficacy of tamoxifen in estrogen receptor-positive breast cancer cells is enhanced by a medical nutriment.
Marcsek Z; Kocsis Z; Jakab M; Szende B; Tompa A
Cancer Biother Radiopharm; 2004 Dec; 19(6):746-53. PubMed ID: 15665622
[TBL] [Abstract][Full Text] [Related]
14. [Modulation of the anti-tumor effect of BRM under various nutritional or endocrine conditions].
Akimoto M; Nishihira T; Kasai M
Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 2):1270-6. PubMed ID: 3729450
[TBL] [Abstract][Full Text] [Related]
15. Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: results from INT 0101 (E5188).
Davidson NE; O'Neill AM; Vukov AM; Osborne CK; Martino S; White DR; Abeloff MD
J Clin Oncol; 2005 Sep; 23(25):5973-82. PubMed ID: 16087950
[TBL] [Abstract][Full Text] [Related]
16. Differential sensitivity of human breast cancer cell lines to the growth-inhibitory effects of tamoxifen.
Reddel RR; Murphy LC; Hall RE; Sutherland RL
Cancer Res; 1985 Apr; 45(4):1525-31. PubMed ID: 3978620
[TBL] [Abstract][Full Text] [Related]
17. Effects of a new clinically relevant antiestrogen (GW5638) related to tamoxifen on breast and endometrial cancer growth in vivo.
Dardes RC; O'Regan RM; Gajdos C; Robinson SP; Bentrem D; De Los Reyes A; Jordan VC
Clin Cancer Res; 2002 Jun; 8(6):1995-2001. PubMed ID: 12060645
[TBL] [Abstract][Full Text] [Related]
18. [Present status of endocrine therapy of breast cancer: a surgeon's view].
Nomura Y
Gan To Kagaku Ryoho; 1984 May; 11(5):981-8. PubMed ID: 6426405
[TBL] [Abstract][Full Text] [Related]
19. [Internal endocrine therapy of breast cancer].
Yoshida M; Miura S
Gan To Kagaku Ryoho; 1984 May; 11(5):989-98. PubMed ID: 6372698
[TBL] [Abstract][Full Text] [Related]
20. Prediction of response to neoadjuvant chemoendocrine therapy in primary breast carcinomas.
Makris A; Powles TJ; Dowsett M; Osborne CK; Trott PA; Fernando IN; Ashley SE; Ormerod MG; Titley JC; Gregory RK; Allred DC
Clin Cancer Res; 1997 Apr; 3(4):593-600. PubMed ID: 9815725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
